At CM LIfe Science, we're delighted to be working with one of the most exciting companies in cancer diagnostics, Elypta. 

It's no coincidence that they're growing, fast. And we've created this page to show you exactly what they have to offer and why we think they're such an exciting proposition for a candidate like you. 

CM Life Science
Searching Together
  • World class science
  • Life changing technology
Reasons to join


Based in Stockholm, Elypta have brought together some of the brightest scientific minds to tackle cancer in a totally new way. Joining Elypta is joining a mission-led business who are already having a huge impact with their groundbreaking multicancer early detection liquid biopsy technology.

The company have also sponsored the largest study ever focused on liquid biopsy-based kidney cancer diagnostics, AURORAX-0087A to test their platform. Since launching, the trial has seen Elypta's technology gain recognition at conferences such as the American Society of Clinical Oncology General Meeting and the European Association of Urology General Meeting.

The company have also had their findings published in publications such as PNAS and Cell Reports, further compounding their position as experts in the oncology diagnostic space. 

A groundbreaking diagnostic breakthrough

The first metabolism based liquid biopsy.

Elypta's mission is to prevent cancer mortality through early detection with their pioneering technology and everyone working for the business is dedicated to that mission.

Elypta's platform measures the GAGome — system biomarkers of tumor metabolism — then use machine learning to detect signatures of cancer noninvasively. It's groundbreaking technology that means multiple cancer indications can be detected easily and non-invasively. 

The company are proud to count leading venture capital firms Industrifonden, Chalmers Ventures, Norrsken VC, and Nina Capital as investors and their R&D and commercialization activities are financed in part by the Horizon 2020 programme of the European Union.

What our people think.

The thing that amazes me most about my colleagues is the way they are striving for performance and to get things done! Francesco Gatto CSO & Co Founder
It's exciting that, when we're developing the assay, we know it's going to be available to patients soon. It's not that far away. Karin Mattsson VP R&D
Elypta is pioneering something new, and that's very exciting. There's a very clear reason why we're doing what we're doing. Fredrik Härenstam VP BD
I thought that the idea sounded really cool and real, in a way that can make a difference. Marianna Mirabelli Director of Clinical Development
  • Nature Research: One to Watch 2020
  • Medtech Insight: Top 7 Innovation in Dx
  • NLS Days 2019: Nordic Life Science Award
  • Tech Arenan: Nordic Start Up of the Year
  • Genetic Engineering & Biotechnology News: Top 10 Under 40

Award Winning Innovation.

Elypta's groundbreaking multicancer early detection liquid biopsy technology has seen them receive various awards, including Francesco Gatto being named as MIT U35 pioneer of the year in 2019 and the business being named start up of the year in the Serendipity Challenge, from a field of over 400 applicants. 

Searching Together

Life at Elypta.

We believe that people work for people, not businesses. So our Director of Marketing and Communications, Kris Holland, spoke to some of Elypta's employees to find out what makes the company so special.


Eleanor Doolin.

If you have any more questions about working for Elypta, you can contact Eleanor Doolin, a Business Manager and specialist within the diagnostics and precision medicine space at 

Eleanor is working exclusively on a number of roles for Elypta and would love to help you find the perfect role with them. 

For more information about Eleanor, you can visit her profile on here

Searching Life Science